New Publication: Reaksi Drug Safety News - Issue 4/2017

REAKSI Drug Safety News,

Issue 4/2017, Vol. 36

• Hyoscine Butylbromide Injection: Risk of Serious Adverse Effects in Patients with Underlying Cardiac Disease
• Keytruda® (pembrolizumab): Risk of Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN)